Thymostimulin in advanced hepatocellular carcinoma: A phase II trial

BACKGROUND: Thymostimulin is a thymic peptide fraction with immune-mediated cytotoxicity against hepatocellular carcinoma in vitro. In a phase II trial, we investigated safety and efficacy including selection criteria for best response in advanced or metastasised hepatocellular carcinoma. METHODS: 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Dollinger, Matthias M, Behrens, Christa M, Lesske, Joachim, Behl, Susanne, Behrmann, Curd, Fleig, Wolfgang E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2323008/
https://www.ncbi.nlm.nih.gov/pubmed/18366627
http://dx.doi.org/10.1186/1471-2407-8-72

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2323008/
https://www.ncbi.nlm.nih.gov/pubmed/18366627
http://dx.doi.org/10.1186/1471-2407-8-72

Ejemplares similares